Published in Pharmacogenet Genomics on February 01, 2015
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. Clin Transl Sci (2016) 0.77
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther (2017) 0.76
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm (2016) 0.76
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pac Symp Biocomput (2016) 0.75
Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress. Future Cardiol (2015) 0.75
Warfarin pharmacogenomics and African ancestry. Blood (2015) 0.75
Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. J Allergy Clin Immunol (2016) 0.75
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75
Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm (2016) 0.75
Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Mol Genet Genomic Med (2017) 0.75
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol (2017) 0.75
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther (2011) 1.43
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics (2009) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther (2012) 1.31
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J (2013) 1.14
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn (2010) 1.06
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther (2011) 1.05
Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J (2013) 1.01
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics (2005) 0.95
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics (2011) 0.95
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 0.94
CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost (2004) 0.86
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics (2014) 0.86
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenet Genomics (2013) 0.85
Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther (2014) 0.82
The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost (2013) 0.82
Control of confounding of genetic associations in stratified populations. Am J Hum Genet (2003) 7.99
Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet (2003) 4.67
Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation. Hum Genomics (2005) 3.77
cis-Regulatory changes in Kit ligand expression and parallel evolution of pigmentation in sticklebacks and humans. Cell (2007) 3.72
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
The landscape of recombination in African Americans. Nature (2011) 3.06
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol (2006) 2.87
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
Genetic evidence for the convergent evolution of light skin in Europeans and East Asians. Mol Biol Evol (2006) 2.54
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Genetic ancestry and the search for personalized genetic histories. Nat Rev Genet (2004) 2.08
Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother (2013) 2.02
The 8818G allele of the agouti signaling protein (ASIP) gene is ancestral and is associated with darker skin color in African Americans. Hum Genet (2005) 1.97
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest (2006) 1.79
Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Human genetic diversity and the nonexistence of biological races. Hum Biol (2003) 1.53
Human genetic diversity and the nonexistence of biological races. 2003. Hum Biol (2009) 1.51
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm (2010) 1.42
Allelic variation at alcohol metabolism genes ( ADH1B, ADH1C, ALDH2) and alcohol dependence in an American Indian population. Hum Genet (2003) 1.39
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate (2010) 1.32
Genetic heterogeneity in colorectal cancer associations between African and European americans. Gastroenterology (2010) 1.31
COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis (2004) 1.30
IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis (2007) 1.28
Markers that discriminate between European and African ancestry show limited variation within Africa. Hum Genet (2002) 1.27
Factors that influence prescribing decisions. Ann Pharmacother (2004) 1.24
Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One (2012) 1.15
Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nat Genet (2003) 1.12
Results from a prostate cancer admixture mapping study in African-American men. Hum Genet (2009) 1.11
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Novel single nucleotide polymorphism associations with colorectal cancer on chromosome 8q24 in African and European Americans. Carcinogenesis (2009) 1.08
African ancestry is associated with asthma risk in African Americans. PLoS One (2012) 1.07
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
Adjusting for population structure in admixed populations. Genet Epidemiol (2002) 1.04
Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol (2007) 1.04
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer (2008) 1.03
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy (2011) 1.03
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate (2010) 1.02
Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis (2010) 0.99
ICAM gene cluster SNPs and prostate cancer risk in African Americans. Hum Genet (2006) 0.99
8q24 risk alleles in West African and Caribbean men. Prostate (2012) 0.98
8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study. BMC Cancer (2010) 0.97
Predictors of serum vitamin D levels in African American and European American men in Chicago. Am J Mens Health (2012) 0.96
Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer (2014) 0.96
Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy (2010) 0.96
Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol (2011) 0.94
Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study. BMC Cancer (2009) 0.93
No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate (2010) 0.92
The relationship between "race" and genetics in biomedical research. Curr Hypertens Rep (2007) 0.92
Anticoagulation management services: entering a new era. Pharmacotherapy (2010) 0.92
Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC). Prostate (2007) 0.91
Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate (2008) 0.91
Predictors of unstable anticoagulation in African Americans. J Thromb Thrombolysis (2008) 0.90
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90
Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans. PLoS One (2011) 0.89
Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm (2008) 0.89
Comparison of statistical methods for estimating genetic admixture in a lung cancer study of African Americans and Latinos. Am J Epidemiol (2008) 0.89
Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis (2012) 0.88
Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet (2014) 0.88
Stakeholder views on pharmacogenomic testing. Pharmacotherapy (2013) 0.88
The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol (2009) 0.88
Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. Cancer Causes Control (2014) 0.87
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87
Racial disparities in prostate cancer incidence, biochemical recurrence, and mortality. Prostate Cancer (2011) 0.87
Smoking and prostate cancer in a multi-ethnic cohort. Prostate (2013) 0.87
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy (2014) 0.87
Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry. Hum Genet (2010) 0.87
E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate (2006) 0.86
A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ (2013) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ (2013) 0.85
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy (2011) 0.85
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenet Genomics (2013) 0.85
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy (2010) 0.85
Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. Ann Pharmacother (2008) 0.84
Cardiovascular pharmacogenomics. Exp Physiol (2005) 0.84
Race as a social construct in head and neck cancer outcomes. Otolaryngol Head Neck Surg (2011) 0.84
Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail (2013) 0.84
Genetic associations in the vitamin D receptor and colorectal cancer in African Americans and Caucasians. PLoS One (2011) 0.83
Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. Pharmacotherapy (2005) 0.83